Search results
Showing 1 to 13 of 13 results for remdesivir
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (TA971)
Evidence-based recommendations on remdesivir (Veklury) and tixagevimab plus cilgavimab (Evusheld) for treating COVID-19.
Awaiting development [GID-TA10721] Expected publication date: TBC
This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.
In development [GID-TA11409] Expected publication date: 29 January 2025
What is the efficacy and safety of remdesivir for people who have been vaccinated against COVID-19?
ID NG191/17 Question What is the efficacy and safety of remdesivir for people who have been vaccinated against COVID-19? Any explanatory
Technology appraisal and highly specialised technologies appeals
Technology appraisal and Highly specialised technologies appeals
Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)
Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid), sotrovimab (Xevudy) and tocilizumab (RoActemra) for treating COVID-19.
Evidence-based recommendations on evinacumab (Evkeeza) for treating homozygous familial hypercholesterolaemia in people 12 years and over.
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
NG191/17 | What is the efficacy and safety of remdesivir for people who have been vaccinated against COVID-19?
Three treatments for COVID have been recommended in draft NICE guidance released today for public consultation.
Dr Ravinder Claire outlines recent progress towards greater use of real-world evidence in regulatory decision-making. He also considers the implications and opportunities for NICE and our stakeholders.
One year on from the first national lockdown, NICE has today (23 March) published a single guideline for the management of COVID-19 in children and adults.